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A 78-year-old male with painful erythematous skin lesions on the
lower extremity
Figure 1. Painful erythematous skin lesions over the
posterior aspect of right thigh.
Figure 2. Acid-Fast bacilli visualized by ﬂuorescence
microscopy consistent with Mycobacteria species.
Figure 3. Growth of Mycobacterium Chelonae on
Middlebrook Agar medium. Specimen was taken
from a cystic skin lesion.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j idA 78-year-old farmer with a history of diabetes mellitus and
rheumatoid arthritis, well controlled with metformin and predni-
sone 20 mg daily, respectively, presented with erythematous
nodular skin lesions over the back of his right thigh of 1-week
duration. He had not had any opportunistic infection previously.
Two of the lesions were cystic and were aspirated. Fluid culture
grew Mycobacterium chelonae. The patient was negative for HIV
antibody (Figs. 1–3).
M. chelonae is a rapidly growing Mycobacterium (RGM). Unlike
other non-tuberculous mycobacteria, RGM produce mature
growth on solid mycobacterial media within 7 days.1 Most
commonly, M. chelonae causes skin and soft tissue infections,
mainly after a penetrating injury. The infection usually remains
localized in immunocompetent patients, but may disseminate in
the immunosuppressed. Infection with M. chelonae is best treated
with at least two antimicrobial agents, especially in the case of
disseminated infection, to avoid the emergence of resistance.
Macrolides are considered the drugs of choice.2 Other potential
antibiotics include tetracyclines, ﬂuoroquinolones, aminoglyco-
sides, carbapenems, and oxazolidinones.3 Treatment is usually
continued for 6 months. This patient was treated with clarithro-
mycin and minocycline for 2 months. Clarithromycin was then
continued for an additional 4 months. The response to treatment
was excellent, with complete resolution of the lesions.
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